men who are completely bald will be able to grow hair on the scalp again

Practically every week at Ukmedix News we hear about some new hair loss remedy that is supposed to revolutionise male pattern baldness and provide hope to millions of men around the world and they are normally just gimmicks. Many companies operating on the internet are trying to sell hair loss medication promising instant results and you should stay well away from all of them. They often claim to have discovered something that all the other scientists and pharmaceutical companies in the world have missed.

Recently however Ukmedix News came across something which could actually be promising over the next few years. It appears that scientists working at the University of Pennsylvania Medical Centre accidentally stumbled across something, [all great inventions start like this] which they feel could mean a new hair loss remedy for men with male pattern baldness and other types of alopecia. The scientists were researching how stem cells could help in regenerating skin and when they were in the process of doing this using laboratory mice they realised that the hair on the mice was growing back too! The scientists were completely stunned when they saw this and had to recheck that they had not missed something.

If this hair loss remedy is brought into commercial use will mean that men who are completely bald will be able to grow hair on the scalp again and it will be unlike existing hair loss remedies such as Propecia and minoxidil which require a small amount of hair to begin with and only prevent further baldness in most cases.

More research needs to be done but at the pace that this research is being done with stem cell regeneration it is likely that in a few years time some form of hair regenerating treatment will be available. How it will exactly be applied is not certain but it could be extremely good for all types of hair loss and especially for those who have suffered skin and hair loss as a result of burns.

The market for hair loss treatment is estimated to be much more than £1 billion every year and there is likely to be no shortage of investors to take this treatment to a commercial level.